What's clear from the long-term data is that adults who built sustainable training and nutrition habits during months 16 maintain their results dramatically better than those who relied on the peptide alone
Ipragliflozin add-on therapy to a GLP-1 receptor agonist in Japanese patients with type 2 diabetes (AGATE): a 52-week open-label study
WeightWatchers own data shows people combining a GLP-1 with its program lose substantially more than with the app alone, which is the same story playing out across the whole industry: the medication is the main driver, and the behavioral program supports it
If any warning signs are noticed, or patients cannot continue the therapy, they must communicate it with a doctor to plan a gradual plan that allows them to get off retatrutide safely without any severe adverse effects
Sources PubMed: Triple-Hormone-Receptor Agonist Retatrutide for Obesity Eli Lilly TRIUMPH-1 Phase 3 topline release, May 21, 2026 Lilly Medical: TRIUMPH clinical trial program overview ClinicalTrials.gov: NCT04881760 Phase 2 obesity trial PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, shipping policy, refund policy, privacy policy, terms, and research disclaimer
What you could recover from at maintenance calories may be excessive in a deficit
